• Johnson & Johnson reviewed first-quarter 2026 results on its April 14 earnings call attended by Chairman and CEO Joaquin Duato, CFO Joseph Wolk, Investor Relations VP Darren Snellgrove, Pharmaceuticals chair Jennifer Taubert, Pharmaceuticals R&D head John Reed, MedTech chair Tim Schmid.
• Operational sales rose 6.4% to $24.1 billion, despite a 540-basis-point headwind from STELARA; adjusted EPS fell 2.5% to $2.70.
• Full-year 2026 guidance increased to operational sales growth of 5.9% to 6.9% with midpoint sales of $100.2 billion; adjusted operational EPS raised $0.02 to $11.30 to $11.50.
• Management highlighted early ICOTYDE launch momentum in plaque psoriasis, citing about 1,500 patient prescriptions routed through its access hub within weeks of approval.
• INLEXZO sales ran slightly above $30 million in quarter; management cited more than 50% week-one jump in new patient insertions following April 1 permanent J-code reimbursement, rising to nearly 90% in week two.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information contained therein.